AlphAIAlphAI — Financial news for AI agents
tipranks.com$BLLN

BillionToOne reports Q3 EPS 32c, consensus 30c

BillionToOne (BLLN) reported Q3 EPS of 32 cents, beating the consensus of 30 cents, and revenue of $122.98M, exceeding the consensus of $115.8M. The company highlighted growth, profitability, and clinical validation of its tests. CEO Atay announced the upcoming launch of Northstar Clear. Guggenheim raised its price target to $128 from $125.

Original reporting
tipranks.com
Published Nov 4, 2026, 10:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BLLN
Bullish
high confidence
Mentioned
$BLLN
Relevance
7/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$BLLNBullishMed
01

Why it matters

Earnings beat may drive short-term price appreciation, but long-term performance depends on pipeline execution.

02

Market read

Earnings surprise provides a trading catalyst for BLLN.

03

What to watch

Future product launches and reimbursement risk could temper upside.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

BillionToOne reported Q3 results with earnings and revenue beats, and announced upcoming product launches.

Company-level read

Ticker impact

$BLLNBullishHigh confidence
Context

Q3 EPS of 32c beats consensus 30c and revenue of $122.98M exceeds $115.8M estimate.

Expected impact

potential upside as market prices in the earnings beat

Evidence & confidence

Both EPS and revenue topped expectations, indicating stronger execution.

Market effects

Sector

Strengthens the biotech/diagnostics sector outlook.

Regional

US biotech investors may see a modest rally.

Global

Limited to niche diagnostic market.

Counterpoint

What could challenge this read

Beat may be modest; market could already price in growth expectations.

Key entities

  • Company
    BillionToOne

    Diagnostic testing company reporting Q3 results.

Read at source← All news

StoryBillionToOne reports strong Q3 2026 results and lifts FY revenue outlook

Also covered by

3 outlets

Related articles

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.

finance.yahoo.com
$BLLNHighAI 8/10

BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance

BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance MENLO PARK, CA, November 4, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,

SEC EDGAR 8-K
$BLLNLow

BillionToOne's Northstar Response Shows High Concordance In Advanced Cancer Study

BillionToOne (BLLN) published a study showing its Northstar Response liquid biopsy assay had high concordance with a commercial ctDNA assay in advanced cancer patients. The study of 61 patients found 94% agreement in tumor burden change direction, with Northstar Response aligning with clinical ground truth in discordant cases. The assay detects disease progression even when tumors evolve post-biopsy. BLLN shares closed at $22.71, down 0.79%.

rttnews.com